References
- Vigouroux S, Michallet M, Porcher R, et al Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Haematologica 2007;92:627–634.
- Escalón MP, Champlin RE, Saliba RM, et al Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol 2004;22:2419–2423.
- Mandigers CM, Verdonck LF, Meijerink JP, Dekker AW, Schattenberg AV, Raemaekers JM. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Bone Marrow Transplant 2003;32:1159–1163.
- Bloor AJ, Thomson K, Chowdhry N, et al High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2008;14:50–58.
- Marcus R, Imrie K, Belch A, et al CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417–1423.
- Coiffier B, Lepage E, Briere J, et al CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
- Pfreundschuh M, Trümper L, Osterborg A, et al CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell: a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:3379–3391.
- Khouri IF, Lee MS, Saliba RM, et al Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol 2004;32:28–35.
- Kamble R, Oholendt M, Carrum G. Rituximab responsive refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2006;12:1201–1202.
- Cutler C, Miklos D, Kim HT, et al Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006;108:756–762.
- Hasegawa M, Hamaguchi Y, Yanaba K, et al B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 2006;169:954–966.
- Pfeiffer M, Stanojevic S, Feuchtinger T, et al Rituximab mediates in vitro antileukemic activity in pediatric patients after allogeneic transplantation. Bone Marrow Transplant 2005;36:91–97.
- Shimoni A, Hardan I, Avigdor A, et al Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma. Br J Haematol 2003;122:457–464.